NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Susan M. Swetter, Douglas B. Johnson, Mark R. Albertini, Christopher A. Barker, Sarah B. Bateni, Joel Baumgartner, Shailender Bhatia, Christopher K. Bichakjian, Genevieve M. Boland, Sunandana Chandra, Bartosz Chmielowski, Dominick J. DiMaio, Roxana Dronca, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Samantha Guild, John Hyngstrom, Giorgos C. Karakousis, Kari Kendra, Maija Kiuru, Julie R. Lange, Ryan M. Lanning, Theodore F. Logan, Daniel G. Olson, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, Luke D. Rothermel, April K.S. Salama, Rohit Sharma, Joseph J. Skitzki, Emily Smith, Katy K. Tsai, Evan Wuthrick, Yan Xing, Nicole R. McMillian, Sara Espinosa
Abstract
The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.